Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

Delayed Quote. Delayed  - 09/27 10:00:00 pm
16.83 USD   -1.29%
09/24 VANDA PHARMACEU : Prepares to Explore a Sale – Sources
09/17 VANDA PHARMACEU : USPTO Dismisses Petition for Inter Partes Review o..
08/31 VANDA PHARMACEU : USPTO Dismisses Petition for Inter Partes Review o..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
09/24 VANDA PHARMACEUTICALS : Prepares to Explore a Sale – Sources
09/22 VANDA PHARMACEUTICALS : Assigned Patent
09/17 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/31 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/30 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/26 WHERE THINGS STAND FOR VANDA PHARMAC : VNDA) In Fanapt Patent Suit
08/26 VANDA PHARMACEUTICALS : Patents Found Valid and Infringed in Fanapt ANDA Litigat..
08/25 VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
08/25 VANDA PHARMACEUTICALS : Patents Found Valid and Infringed in Fanapt® ANDA Litiga..
08/23 VANDA PHARMACEUTICALS : HETLIOZ Now Available for Treatment of Non-24-Hour Sleep..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/26 BIOTECH FORUM DAILY DIGEST : Behind Some Big Moves In Small Caps. Spotlight On V..
09/20 INSIDERINSIGHTS.COM DAILY ROUND UP 9 : Phillips 66, Nuveen Global Equity Income ..
08/31 VANDA : Fanapt Patent Ruling Adds To Upside Potential
08/28 Why Recent Fanapt Ruling Is Important To Vanda
08/26 BIOTECH FORUM DAILY DIGEST : Clinton Takes A Swipe At Biotech, Revisiting The Bu..
Advertisement
Financials ($)
Sales 2016 147 M
EBIT 2016 -31,2 M
Net income 2016 -25,9 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 4,97x
Capi. / Sales 2017 3,96x
Capitalization 728 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 20,0 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..80.77%738
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
More Results